Highly invasive and DNA repair-proficient GBM cells with high PFKM expression in the tumor periphery evade bevacizumab therapy by invading normal brain parenchyma. Loss of PFKM impairs survival and invasion and exacerbates genomic instability of GBM cells, thereby potentiating the effect of bevacizumab therapy.